{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-307381","form_type":"8-K","ticker":"NERV","cik":"0001598646","company_name":"Minerva Neurosciences, Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.355553+00:00","generated_at":"2026-06-21T03:20:58.561838+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Minerva Neurosciences amends CEO Luthringer's employment agreement with enhanced severance terms","bullets":["CEO Remy Luthringer to receive 12 months base salary continuation upon termination without cause.","Pro-rata annual bonus (assumed at 50% of base salary) + accelerated vesting for awards vesting within 6 months.","Base salary set at $600,096 per year.","Amendment effective December 13, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-307381","json":"https://secwatch.observer/filing/0001193125-22-307381.json","markdown":"https://secwatch.observer/filing/0001193125-22-307381.md","text":"https://secwatch.observer/filing/0001193125-22-307381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1598646/000119312522307381/0001193125-22-307381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1598646/000119312522307381/d438557d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:20:58.561838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}